References
- Gupta AK, Talukder M, Bamimore MA. Natural products for male androgenetic alopecia. Dermatol Ther. 2022;35(4):e15323. doi: 10.1111/dth.15323
- Zhang Y, Xu J, Jing J, et al. Serum levels of androgen-associated hormones are correlated with curative effect in androgenic alopecia in young men. Med Sci Monit. 2018 Oct 30;24:7770–7777. doi: 10.12659/MSM.913116
- Crabtree JS, Kilbourne EJ, Peano BJ, et al. A mouse model of androgenetic alopecia. Endocrinology. 2010 May;151(5):2373–2380.
- Gupta AK, Talukder M. A cannabinoid hairy‐tale: hair loss or hair gain? J Cosmet Dermatol. 2022;21(1):6653–6660. doi: 10.1111/jocd.15427
- Gupta AK, Venkataraman M, Talukder M, et al. Finasteride for hair loss: a review. J Dermatol Treat. 2022;33(4):1938–1946. doi: 10.1080/09546634.2021.1959506
- Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: is it a safe and effective alternative? J Cosmet Dermatol. 2022;21(5):1841–1848. doi: 10.1111/jocd.14895
- Piraccini BM, Blume‐Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomised, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286–294. doi: 10.1111/jdv.17738
- Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000 Oct;143(4):804–810.
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride male pattern hair loss study group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578–589.
- Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):930–937.
- Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555–563. doi: 10.1016/S0190-9622(99)70296-3
- EMA. List of nationally authorised medicinal products (active substance: finasteride); procedure no.: PSUSA/00001392/202108; reference no. Ema/208932/2022 2022 [cited 2024 17 Mar]. Available from: https://www.ema.europa.eu/en/medicines/psusa/psusa-00001392-202108
- Study used to push non-fda-approved topical finasteride knocked by top German rx journal (post-finasteride syndrome foundation) 2023 [cited 2024 17 Mar]. Available from: https://www.pfsfoundation.org/news/study-used-to-push-non-fda-approved-topical-finasteride-knocked-by-top-german-rx-journal/
- Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014 Oct;52(10):842–849.
- US FDA. PROPECIA® (finasteride) tablets for oral use 2022 [cited 2024 18 Mar]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf
- US FDA. PROSCAR® (finasteride) tablets for oral use 2021 [cited 2024 19 Mar]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s047lbl.pdf
- Grymowicz M, Rudnicka E, Podfigurna A, et al. Hormonal effects on hair follicles. Int J Mol Sci. 2020 Jul 28;21(15):5342. doi: 10.3390/ijms21155342
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–1023. doi: 10.1016/j.jaad.2006.05.007
- Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatol Treat. 2022 Aug 3;33(7):2946–2962. doi: 10.1080/09546634.2022.2109567
- Mother to baby | fact sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994-. Finasteride 2022 [cited 2024 20 Mar]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582707/
- Laborde E, Brannigan RE. Effect of 1‐mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 2010;31(2):e1–e2. doi: 10.2164/jandrol.109.009381
- Amory JK, Wang C, Swerdloff RS, et al. The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–1665. doi: 10.1210/jc.2006-2203
- Mirabello S What happens when you stop taking finasteride? 2023 [cited 2023 4 Oct]. Available from: https://nowpatient.com/blog/what-happens-when-you-stop-taking-finasteride
- Choi G-S, Sim W-Y, Kang H, et al. Long-term effectiveness and safety of dutasteride versus finasteride in patients with male androgenic alopecia in south korea: a multicentre chart review study. Ann Dermatol. 2022;34(5):349. doi: 10.5021/ad.22.027
- Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–258. doi: 10.1016/j.jaad.2009.09.018
- Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014 Mar;70(3):489–498.e3.
- Shanshanwal S, Dhurat R. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47. doi: 10.4103/0378-6323.188652
- Vañó-Galván S, Saceda-Corralo D, Moreno-Arrones OM, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study. Dermatol Ther. 2020 Jan;33(1):e13182. doi: 10.1111/dth.13182
- Dutasteride Pregnancy and Breastfeeding Warnings. 2022. [cited 2023 4 October]. Available from: https://www.drugs.com/pregnancy/dutasteride.html
- US FDA. AVODART (dutasteride) soft gelatin capsules: highlights of prescribing information. 2020 [cited 2023 3 Oct]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf
- AVODART (Dutasteride) 0.5 mg soft capsules; package leaflet: information for the patient 2023 [cited 2024 16 Jan]. Available from: https://www.medicines.org.uk/emc/files/pil.6758.pdf
- Abdallah M, El-Zawahry K, Besar H. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. J Pan Arab Leag Dermatol. 2009;20:137–145.
- Herz-Ruelas ME, Alvarez-Villalobos NA, Millan-Alanis JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020 Nov;6(6):338–345.
- Moftah N, Moftah N, Abd‐Elaziz G, et al. Mesotherapy using dutasteride‐containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686–693. doi: 10.1111/j.1468-3083.2012.04535.x
- Sobhy N, Aly H, El Shafee A, et al. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatology Online. 2013;4(1):40. doi: 10.7241/ourd.20131.08
- Villarreal-Villarreal CD, Boland-Rodriguez E, Rodriguez-Leon S, et al. Dutasteride intralesional microinjections in combination with oral minoxidil vs. oral minoxidil monotherapy in men with androgenetic alopecia: a retrospective analysis of 105 patients. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e570–e572.
- Bird ST, Brophy JM, Hartzema AG, et al. Male breast cancer and 5alpha-reductase inhibitors finasteride and dutasteride. J Urol. 2013 Nov;190(5):1811–1814.
- Fang Q, Chen P, Du N, et al. Analysis of data from breast diseases treated with 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Breast Cancer. 2019 Oct;19(5):e624–e636.
- Wang J, Zhao S, Luo L, et al. 5-alpha Reductase Inhibitors and risk of male breast cancer: a systematic review and meta-analysis. Int Braz J Urol. 2018 Sep;44(5):865–873.
- Kim MW, Park HS, Park JS, et al. Five-alpha reductase inhibitor and breast cancer risk in men: a systematic review. Ann Dermatol. 2017 Aug;29(4):525–528.
- Rozner RN, Freites-Martinez A, Shapiro J, et al. Safety of 5alpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat. 2019 Feb;174(1):15–26.
- UK MHRA. The risk of male breast cancer with finasteride (public assessment report) 2009 [cited 2024 22 Jan]. Available from: https://assets.publishing.service.gov.uk/media/5df7610c40f0b60959adc737/Finasteride_risk_of_male_breast_cancer.pdf
- James JF, Jamerson TA, Aguh C. Efficacy and safety profile of oral spironolactone use for androgenic alopecia: a systematic review. J Am Acad Dermatol. 2022 Feb;86(2):425–429. doi: 10.1016/j.jaad.2021.07.048
- Wang C, Du Y, Bi L, et al. The efficacy and safety of oral and topical spironolactone in androgenetic alopecia treatment: a systematic review. Clin Cosmet Investig Dermatol. 2023;16:603–612. doi: 10.2147/CCID.S398950
- Abdel‐Raouf H, Aly UF, Medhat W, et al. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatologic Therapy. 2020;34(1):e14678. doi: 10.1111/dth.14678
- Dominguez‐Santas M, Diaz‐Guimaraens B, Saceda‐Corralo D, et al. The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms. JEADV Clin Prac. 2022;1(3):1–10. doi: 10.1002/jvc2.53
- Moussa A, Kazmi A, Bokhari L, et al. Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: a retrospective review of 35 patients. J Am Acad Dermatol. 2022 Aug;87(2):488–490.
- Fernandez-Nieto D, Saceda-Corralo D, Jimenez-Cauhe J, et al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss. J Am Acad Dermatol. 2020 Nov;83(5):e355–e356.
- Ismail FF, Meah N, Trindade de Carvalho L, et al. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020 Nov;83(5):1478–1479.
- Ghosh S Alopecia treatment market outlook (2022 to 2032): future market insights; 2022 [cited 2023 28 Dec]. Available from: https://www.futuremarketinsights.com/reports/alopecia-treatment-market
- Hair loss treatment products market size & share analysis - growth trends & forecasts (2023 – 2028) mordor intelligence; 2023 [cited 2023 28 Dec]. Available from: https://www.mordorintelligence.com/industry-reports/hair-loss-treatment-products-market
- PubChem compound summary of alfataradiol 2023 [cited 2023 27 Dec]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Alfatradiol
- Episteride structure 2023 [cited 2023 27 Dec]. Available from: https://commons.wikimedia.org/wiki/File:Epristeride.svg
- PubChem compound summary of clascoterone 2023 [cited 2023 27 Dec]. Available from: https://pubchem.ncbi.nlm.nih.gov/substance/483925126
- PubChem compound summary of pyrilutamide 2023 [cited 2023 28 Dec]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/50940514#section=2D-Structure
- Blumeyer A, Tosti A, Messenger A, et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(s6):S1–S57. doi: 10.1111/j.1610-0379.2011.07802.x
- Blume-Peytavi U, Kunte C, Krisp A, et al. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007 May;5(5):391–395.
- Frye SV. Inhibitors of 5-alpha reductase. In: Sliskovic DR, editor. Current pharmaceutical design. Vol. 2. The Netherlands: Netherlands Benthan Science Publishers BV; 1996. p. 59–84.
- A phase 2 study to evaluate the safety and efficacy of cb-03-01 Solution, a Comparator Solution and Vehicle Solution in Males with Androgenetic Alopecia (NCT02279823): ClinicalTrials.gov; 2016 [cited 2023 10 Oct]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT02279823
- Rafi AW, Katz RM. Pilot Study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatol. 2011;2011:241953. doi: 10.5402/2011/241953
- Piérard-Franchimont C, De Doncker P, Cauwenbergh G, et al. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474–477. doi: 10.1159/000017954
- Fultinavičiūtė U Kintor succeeds in Phase II study of US males with androgenetic alopecia 2023 [cited 2023 2 Oct]. Available from: https://www.clinicaltrialsarena.com/news/kintor-androgenetic-alopecia-kx-826/
- Kintor Pharma announces first patient dosing of phase III clinical trial of KX-826 (Pyrilutamide) for treating androgenic alopecia patients in China 2022 [cited 2023 2 Oct]. Available from: https://www.prnewswire.com/news-releases/kintor-pharma-announces-first-patient-dosing-of-phase-iii-clinical-trial-of-kx-826-pyrilutamide-for-treating-androgenic-alopecia-patients-in-china-301452532.html
- Wang R, Zhong T, Bian Q, et al. PROTAC degraders of androgen receptor-integrated dissolving microneedles for androgenetic alopecia and recrudescence treatment via single topical administration. Small Methods. 2023 Jan;7(1):e2201293. doi: 10.1002/smtd.202201293
- Lama SC, Chang MW. Kintor advances with GT20029 clinical trials for hair loss 2023 [cited 2024 20 Mar]. Available from: https://hairscience.org/news/gt20029-topical-androgen-degrader/
- Wessagowit V, Tangjaturonrusamee C, Kootiratrakarn T, et al. Treatment of male androgenetic alopecia with topical products containing S erenoa repens extract. Australas J Dermatol. 2016;57(3):e76–e82. doi: 10.1111/ajd.12352
- Rossi A, Mari E, Scarno M, et al. Comparative effectiveness and finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167–1173. doi: 10.1177/039463201202500435
- Prager N, Bickett K, French N, et al. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-α-reductase in the treatment of androgenetic alopecia. J Altern Complement Med. 2002;8(2):143–152. doi: 10.1089/107555302317371433
- Cho YH, Lee SY, Jeong DW, et al. Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2014;2014:549721. doi: 10.1155/2014/549721
- Anastassakis K. Pygeum Africanum (Prunus Africana). Androgenetic alopecia from A to Z. Vol. 2. Drugs, Herbs, Nutrition and Supplements: Springer; 2022. p. 441–444.
- Maria Borrás J, Piqué N, Nieto C, et al. Efficacy and safety of a dietary supplement containing a lipid co-extract from Serenoa repens and Pygeum africanum for the treatment of androgenetic alopecia (AGA) in women. Results of a randomized, double-blind, placebo-controlled clinical trial. Más dermatología. 2016;25(25):5–14. doi: 10.5538/1887-5181.2016.25.5
- Package leaflet of CARETOPIC (finasteride) 2.275 mg/ml cutaneous spray, solution 2023 [cited 2024 17 Mar]. Available from: https://www.codifa.it/foglietti-illustrativi/Caretopic